2019 Tuberculosis Drug Discovery and Development GRC: Shortening the Duration of Tuberculosis Chemotherapy and GRS

摘要 该申请寻求对2019年结核病（TB）药物发现和开发戈登的部分支持 研究会议（GRC）和戈登研究研讨会（GRS）将在Rey Don Jaime Grand举行 2019年7月6日至7日和7日至12日在西班牙Castelldefels的酒店。 这将是第十届结核病药物研发研讨会，第一届于2001年举行，此后每两年举行一次。 基础和与此GRC相关的第四个GRS。这是最重要的全球会议， 结核病药物发现，并一直在GRC会议上获得高绩效评级 超过70%的与会者对本次会议的评价高于历年平均水平。这 GRC汇集了来自学术界和工业界的结核病药物开发研究人员， 互动环境，重点是打击这一全球公共卫生威胁的挑战。结核病现在是 尽管有6-9个月的可用性， 治疗方案达到约83%的治愈率。本GRC的组装理念是， 世卫组织结束全球结核病流行的战略只能通过开发治疗方案来实现， 缩短治疗时间。使用相似药物的治疗持续时间更短，安全性更高 这将导致更好的遵守，重要的是，打击新出现的抗药性威胁。 在治疗缩短的主题下，本次会议将汇集具有不同 背景，包括微生物学，化学，药理学，医学和临床研究。届会 已经被精心策划，以提供一个实现治疗的关键要素的床旁视图 结核病药物发现领域的缩短。GRC将提供一个独特的机会， 世界领先的结核病药物发现研究人员以及一些来自该领域以外的研究人员， 所做的工作可能对未来如何发现结核病药物产生根本性影响。 GRC和相关的GRS营造了一个鼓励研究人员分享的环境 前沿未发表的数据和交流思想之间既建立以及年轻的研究人员 和学员在此促进所有与会者的职业发展。GRC将包括一个“电源小时”， 所有与会者的非正式会议，讨论妇女在科学领域面临的挑战， 支持女性在科学领域的专业成长。GRC和GRS计划都将反映 该领域科学家的多样性，目标是妇女代表性强，代表性不足 少数民族和国际科学家。

Abstract This application seeks partial support for the 2019 Tuberculosis (TB) Drug Discovery & Development Gordon Research Conference (GRC) and Gordon Research Seminar (GRS) to be held in at the Rey Don Jaime Grand Hotel in Castelldefels, Spain from July 6-7 and 7-12, 2019. This will be the tenth GRC on TB Drug discovery with the first being held in 2001 and thereafter on a biennial basis and the fourth GRS associated with this GRC. This is the most important global conference on tuberculosis drug discovery and has consistently received a high-performance rating in the GRC Conference Evaluation outcome with more than 70% of conferees rating this meeting above average over the years. This GRC brings together TB drug development researchers from academia and industry in a friendly highly interactive environment to focus on the challenge of combatting this global public health threat. TB is now the leading cause of death internationally due to a single infectious agent despite the availability of a 6-9 month treatment regimen that achieves ~83% cure rates. This GRC has been assembled around the concept that the WHO's strategy to end the global TB epidemic can only be achieved by developing regimens with dramatically reduced treatment durations. A shorter treatment duration with drugs of similar of preferably increased safety profiles will lead to better adherence and importantly, combat the emerging threat of drug resistance. Under the theme of treatment shortening, this conference will bring together investigators with diverse backgrounds, including microbiology, chemistry, pharmacology, medicine and clinical research. The sessions have been orchestrated to provide a bench-to-bedside view of critical elements in achieving treatment shortening in the TB drug discovery field. The GRC will provide a unique opportunity to bring together the world's leading TB drug discovery researchers as well as a few researchers from outside the field who are doing work that may have a fundamental impact of how TB drug discovery may be approached in the future. The GRC and associated GRS foster an environment wherein which researchers are encouraged to share cutting edge unpublished data and exchange ideas between both established as well as young investigators and trainees hereby promoting career development for all attendees. The GRC will include a “Power Hour”, an optional informal gathering for all meeting participants to address the challenges women face in science and to support the professional growth of women in science. Both the GRC and the GRS programs will reflect the diversity of the scientists in the field with an aim of strong representation of women, underrepresented minorities and international scientists.